Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

Podobne zapisy

• The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial
  od: Oscier, David, i wsp.
  Wydane: (2016)
• The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
  od: Else, Monica, i wsp.
  Wydane: (2015)
• The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry
  od: Matutes, E, i wsp.
  Wydane: (2013)
• The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial
  od: Else, Monica, i wsp.
  Wydane: (2021)
• Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial
  od: Blakemore, Stuart J., i wsp.
  Wydane: (2020)